Study guide
18.3 Epidemiology Measures & Population Health
NBME Comprehensive Basic Science Examination CBSE
Track your progress as you read
Finished sections get a check mark.
1 Introduction & Exam Navigation
1.1 Current Exam Facts & Administration 1.2 Content Blueprint & Physician Tasks 1.3 Scoring, Score Reports & Step 1 Readiness
2 Human Development
2.1 Embryology & Congenital Development Patterns 2.2 Normal Age-Related Findings & Well-Patient Care
3 Blood & Hematologic Disease
3.1 Hematopoiesis, RBC Disorders & Anemias 3.2 Hemostasis, Thrombosis & Coagulopathies 3.3 WBC Disorders, Leukemia & Lymphoma Mechanisms
4 Immune System
4.1 Innate & Adaptive Immunity Mechanisms 4.2 Hypersensitivity, Autoimmunity & Immunodeficiency 4.3 Transplant Immunology & Immune Pharmacology
5 Nervous System Anatomy & Disease
5.1 Neuroanatomy Localization & Pathways 5.2 Stroke, Infection, Demyelination & Trauma 5.3 Seizures, Movement Disorders & Neurodegeneration 5.4 Special Senses: Eye & Ear Mechanisms
6 Behavioral Health
6.1 Psychiatric Disorders & Diagnostic Patterns 6.2 Psychopharmacology Mechanisms 6.3 Neurotransmitters, Learning & Behavioral Science
7 Musculoskeletal System
7.1 Bone Physiology, Fracture Healing & Bone Pathology 7.2 Joint Disease, Rheumatology & Connective Tissue 7.3 Muscle, NMJ & Peripheral Nerve Disorders
8 Skin & Soft Tissue
8.1 Dermatopathology High-Yield Lesions 8.2 Inflammation, Wound Healing & Soft-Tissue Infection
9 Cardiovascular Pathophysiology
9.1 Cardiac Cycle, Hemodynamics & Murmurs 9.2 Ischemic Heart Disease & Cardiomyopathy 9.3 Congenital & Valvular Heart Disease 9.4 Vascular Pathology & Hypertension
10 Cardiovascular Pharmacology
10.1 Antihypertensives, Heart Failure & Antiarrhythmics 10.2 Antiplatelets, Anticoagulants & Lipid Drugs
11 Respiratory System
11.1 Pulmonary Mechanics & Gas Exchange 11.2 Obstructive, Restrictive & Vascular Lung Disease 11.3 Pulmonary Infections, Neoplasms & Respiratory Pharmacology
12 Renal Physiology & Electrolytes
12.1 Nephron Transport & Renal Physiology 12.2 Electrolyte Disorders 12.3 Acid-Base Physiology & Compensation
13 Renal Pathology
13.1 Glomerular Disease Mechanisms 13.2 Tubulointerstitial, Vascular & Stone Disease
14 Gastrointestinal System
14.1 GI Physiology, Motility & Digestion 14.2 Esophagus, Stomach & Intestinal Pathology 14.3 Liver, Biliary Tree & Pancreas 14.4 GI Microbiology, Nutrition & Malabsorption
15 Endocrine System
15.1 Hormone Signaling & Hypothalamic-Pituitary Axes 15.2 Thyroid & Parathyroid Disease 15.3 Adrenal Disorders & Steroid Pharmacology 15.4 Diabetes, Glucose Homeostasis & Metabolic Syndrome
16 Reproductive System
16.1 Male & Female Reproductive Physiology 16.2 Pregnancy, Placenta & Developmental Toxicology 16.3 Reproductive Pathology & Hormone-Related Neoplasia
17 Multisystem Processes & Disorders
17.1 Cell Injury, Inflammation & Repair 17.2 Neoplasia Principles & Tumor Biology 17.3 Infection, Sepsis & Multisystem Microbial Disease 17.4 Genetics, Inborn Errors & Environmental Toxicology
18 Biostatistics & Epidemiology
18.1 Study Design, Bias & Causation 18.2 Diagnostic Test Metrics & Screening 18.3 Epidemiology Measures & Population Health
19 Social Sciences & Communication
19.1 Ethics Principles & Decision-Making Capacity 19.2 Communication Skills & Difficult Conversations 19.3 Professionalism, Systems & Practice-Based Learning
20 Integrated Disciplines Capstone
20.1 High-Yield Microbiology Anchors Across Systems 20.2 High-Yield Biochemistry & Molecular Mechanisms 20.3 Integrated Pharmacology Strategy & Exam-Day Execution
18.3 Epidemiology Measures & Population Health
Key Takeaways Explain This Topic AI
Incidence = new cases / population at risk / time (flow); prevalence = existing cases / population (stock); prevalence ≈ incidence × duration when steady state holds.
Mortality rates, case fatality, and attack rates answer different questions; attack rate is cumulative incidence in an outbreak-defined population.
Herd immunity threshold for a perfectly mixed population approximates 1 − 1/R0; outbreak investigation follows verify → define/count → describe (time/place/person) → hypothesize → test → control → communicate.
Primary prevention prevents disease onset; secondary detects early disease; tertiary reduces complications of established disease; risk factors are attributes increasing disease probability, while determinants of health include broader social/structural drivers.
p < α (often 0.05) addresses Type I error under a null, not clinical importance; power = 1 − β controls Type II error; confidence intervals estimate precision of effect sizes and whether null values are excluded.
Last updated: August 2026
18.3 Epidemiology Measures & Population Health
Quick Answer: Incidence = new cases over time; prevalence = existing cases at a time (≈ I × duration). Attack rate = ill / exposed in an outbreak. Herd immunity threshold ≈ 1 − 1/R0. Primary/secondary/tertiary prevention map to before disease / early detection / limit disability. p-values ≠ effect size; power = 1 − β; CIs show precision and null exclusion.
This section ties classical epidemiology measures to prevention, outbreak response, disparities framing, and the inferential statistics tested alongside biostats on CBSE/PBLI-style items.
Incidence vs Prevalence
Measure Definition Units / form Rises when…
Incidence (cumulative) New cases / population at risk over a period Dimensionless proportion over time window More new disease
Incidence rate (density) New cases / person-time at risk Cases per person-year More new disease or better ascertainment
Prevalence (point) Existing cases / population at a time Proportion Higher incidence or longer duration (better survival, chronicity)
Relationship (steady state, low disease): Prevalence ≈ incidence × average duration.
Worked example 1 — Incidence and prevalence
City of 100,000 with no disease at t = 0. Over 1 year, 500 new cases of a chronic condition develop; none die or leave; all remain diseased.
- Annual cumulative incidence ≈ 500/100,000 = 0.5%
- End-of-year prevalence ≈ 500/100,000 = 0.5% (first year)
If average duration becomes 10 years with steady 500 new cases/year, prevalence approaches 500 × 10 / 100,000 = 5% . Improved treatment that prolongs life with disease increases prevalence even if incidence is flat—classic exam trap.
Worked example 2 — Person-time rate
200 patients followed: 50 for 1 year, 100 for 2 years, 50 for 4 years without the event until 12 events occur.
- Person-years = 50·1 + 100·2 + 50·4 = 50 + 200 + 200 = 450
- Incidence rate = 12/450 = 0.0267 per person-year (≈ 2.67 per 100 person-years)
- Mortality Rates and Related Metrics
- Metric Formula (teaching form) Use
- Crude mortality rate Deaths / mid-year population / time Overall death burden
- Cause-specific mortality Deaths from cause / population / time Burden of one disease
- Age-specific mortality Deaths in age band / population in band Compare age groups
- Case fatality rate (CFR) Deaths from disease / cases of disease Severity among the ill
- Proportionate mortality Deaths from cause / all deaths Share of deaths, not risk
CFR ≠ cause-specific mortality. CFR uses cases in the denominator; mortality uses population .
Worked example 3 — CFR vs mortality
Population 1,000,000; 2,000 myocardial infarctions; 400 MI deaths in a year.
- CFR = 400/2000 = 20%
- Cause-specific MI mortality = 400/1,000,000 = 0.04% per year (40 per 100,000)
- Attack Rate
Attack rate is cumulative incidence in a clearly defined exposed group during an outbreak window:
Attack rate = number who became ill / number exposed (at risk)
Often expressed as percent. Food-specific attack rates compare foods at a picnic.
Worked example 4 — Outbreak table
- Ate potato salad Ill Well Total Attack rate
- Yes 45 15 60 45/60 = 75%
- No 10 40 50 10/50 = 20%
Risk ratio = 0.75/0.20 = 3.75 . Potato salad is the leading hypothesis for the vehicle. Secondary attack rate among household contacts uses new cases among contacts / susceptible contacts.
Herd Immunity Threshold (Concept)
Basic reproduction number R0 = average secondary cases from one infectious person in a fully susceptible population.
Effective reproduction number Rt falls as immunity rises.
With homogeneous mixing and solid immunity, herd immunity threshold (HIT):
- HIT ≈ 1 − 1/R0
- Worked example 5
If R0 = 5, HIT ≈ 1 − 1/5 = 0.80 (80%) immune needed so each case produces <1 secondary case on average.
If R0 = 15 (highly transmissible agent), HIT ≈ 93% .
Imperfect vaccines require higher coverage: roughly HIT / vaccine effectiveness.
Real populations are not perfectly mixed; clustering and waning immunity complicate estimates—but the formula is standard exam material.
Outbreak Investigation Steps
A practical sequence (order may overlap):
Prepare / verify diagnosis — confirm the disease is real (lab, clinical criteria); rule out pseudo-outbreaks.
Confirm outbreak — cases exceed expected baseline.
Case definition — person, place, time, clinical/lab criteria (possible/probable/confirmed).
Find and count cases — active surveillance, line list.
Descriptive epidemiology — time (epidemic curve), place (spot map), person (age, sex, exposures).
Generate hypotheses — source, mode, vehicle, risk factors.
Test hypotheses — analytic epidemiology (cohort/case-control attack rates), environmental/lab testing.
Implement control and prevention — remove source, isolate, vaccinate, educate— often start control before all analytics finish when risk is high.
Communicate findings — public, clinicians, agencies.
Maintain surveillance — ensure outbreak ends; evaluate response.
Epidemic curve shapes: point source (single peak), continuous common source (prolonged plateau), propagated (serial peaks at incubation intervals).
Levels of Prevention
- Level Goal Examples
- Primary Prevent disease onset Immunization, smoking never-start, seat belts, clean water, PrEP
Secondary Detect early / preclinical disease to improve outcomes Pap smear, mammography, BP screening, newborn metabolic screen
Tertiary Reduce complications/disability of established disease Cardiac rehab post-MI, glycemic control to prevent retinopathy, stroke rehabilitation
Primordial prevention (sometimes tested) targets underlying social/environmental conditions that give rise to risk factors (e.g., urban design reducing default sedentary life).
Exam trap: treating severe disease complications is tertiary, not primary—even if heroic.
Risk Factors vs Determinants of Health
Risk factor: measurable attribute/exposure associated with increased probability of disease (hypertension → stroke; smoking → lung cancer). May be causal or marker.
Determinants of health: broader set of personal, social, economic, and environmental factors that influence health status—income, education, housing, racism/discrimination, access to care, built environment, health behaviors, genetics.
Health disparities (basic-science framing on CBSE): systematic, potentially avoidable differences in health outcomes between groups defined by social advantage. Mechanisms taught at the interface of biology and environment include chronic stress physiology (HPA/sympathetic activation), differential toxic exposures, nutrition access, infectious exposure density, and unequal treatment access—not "biological race as destiny." Disparities questions often ask which intervention level or structural factor best explains a gradient after individual risk factors are listed.
Statistical Significance vs Clinical Significance
- Concept Meaning
- Null hypothesis (H0) Usually "no association / no difference"
p-value Probability of data as extreme as observed if H0 true (with model assumptions); not P(H0 true), not effect size
- α (Type I error rate) Prespecified false-positive threshold (commonly 0.05)
- Statistically significant p < α (by convention)—may be tiny and meaningless clinically if n is huge
- Clinical significance Effect size large enough to matter to patients/clinicians (ARR, NNT, QoL)
- Worked example 6 — Significant but trivial
Drug lowers systolic BP by 0.5 mm Hg ; n = 100,000; p = 0.001. Statistically significant, clinically negligible for individuals. Conversely, a 15 mm Hg drop in a small pilot with p = 0.08 may be clinically promising but not "significant" at α = 0.05—need more power, not dismissal of the effect size.
Type I Error, Type II Error, and Power
- H0 true H0 false
- Reject H0 Type I error (false positive), probability α Correct detection (power)
- Fail to reject H0 Correct Type II error (false negative), probability β
Power = 1 − β = probability of detecting a true effect of a specified size.
Power rises with: larger effect size, larger sample size, higher α, lower variance, more precise measurements, one-sided tests (when appropriate).
Worked example 7 — Interpreting β
Study designed with 80% power (β = 0.20) at α = 0.05 to detect ARR of 5%. If the true ARR is 5%, there is still a 20% chance of a nonsignificant result. A negative underpowered study does not prove no effect.
Confidence Intervals
A 95% confidence interval (CI) for a mean difference or RR is a range from a procedure that, in repeated sampling, covers the true parameter 95% of the time (frequentist teaching). Practical exam uses:
Width → precision (narrower = more precise, often larger n )
Whether null is inside → for difference, null is 0; for ratio, null is 1. If 95% CI for RR is 0.6–0.9, excludes 1 → consistent with statistical significance at α = 0.05 (two-sided) under standard correspondence
Clinical bounds → even if CI excludes null, if entire CI is within a trivial effect range, clinical importance remains doubtful
Worked example 8 — CI reading
RR = 1.20; 95% CI 0.95–1.52 → not statistically significant at 0.05; compatible with modest harm, null, or modest benefit— imprecise .
RR = 0.70; 95% CI 0.65–0.76 → precise protective association; still check absolute risks for decision-making.
Integration for CBSE Vignettes
Chronic disease more prevalent despite flat incidence → longer duration/survival .
Outbreak picnic → attack rates by food; highest AR and AR ratio drive hypothesis.
"What percent must be immune?" → 1 − 1/R0 .
Vaccine before exposure → primary prevention; mammography → secondary ; post-stroke rehab → tertiary .
Tiny p with tiny ARR → emphasize clinical vs statistical significance.
Nonsignificant trial with n = 20 → suspect low power , not proof of equivalence.
RR 0.5 (0.4–0.6) → significant and relatively precise; still compute NNT when rates given.
Population measures describe burden and spread; prevention levels organize interventions; inferential statistics police how we claim knowledge. Together they complete the 4–6% biostats/epidemiology band on the CBSE.